fda remove semaglutide from shortage list As of February 21, 2025, the updated its drug list, marking the injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A Semaglutide shortage ends as FDA

We find that while almost all patients tolerate this treatment very well, some can titrate more quickly leading to faster results

Emergency signs include fever with abdominal pain, persistent vomiting, and jaundice (yellowing of skin or eyes), which require urgent imaging and evaluation

Mounjaro contains the active ingredient tirzepatide, whereas Ozempic is formulated using semaglutide

Plenty of generic medication reminders exist, but Pep is purpose-built for GLP-1 users

While generally safe when administered by qualified dermatologists at registered clinics, the treatment requires maintenance sessions every 23 months to sustain results